Article
Oncology
Kelley G. Nunez, Tyler Sandow, Daniel Fort, Jai Patel, Mina Hibino, Ian Carmody, Ari J. Cohen, Paul Thevenot
Summary: The biomarkers AFP, AFP-L3, and DCP have implications in HCC surveillance, prognosis, and post-surgical recurrence risk. Accumulation of these biomarkers increases HCC progression risk, but patients with triple negative status for these biomarkers have a higher first-line objective response rate.
Article
Oncology
Takakazu Nagahara, Takaaki Sugihara, Takuya Kihara, Suguru Ikeda, Yoshiki Hoshino, Yukako Matsuki, Takuki Sakaguchi, Hiroki Kurumi, Takumi Onoyama, Tomoaki Takata, Tomomitsu Matono, Naoyuki Yamaguchi, Hajime Isomoto
Summary: This study investigated the characteristics and prognosis of double-negative HCC (DNHC) in higher stages of hepatocellular carcinoma (HCC) using AFP and DCP as tumor markers. It was found that DNHC in higher BCLC stages showed smaller tumor size and had better survival rates.
Article
Oncology
Amy K. Kim, James P. Hamilton, Selena Y. Lin, Ting-Tsung Chang, Hie-Won Hann, Chi-Tan Hu, Yue Lou, Yih-Jyh Lin, Terence P. Gade, Grace Park, Harry Luu, Tai-Jung Lee, Jeremy Wang, Dion Chen, Michael G. Goggins, Surbhi Jain, Wei Song, Ying-Hsiu Su
Summary: The study found that urine circulating tumor DNA can be used as a potential screening test for hepatocellular carcinoma, especially in patients with low serum AFP levels, and it can improve the detection rate of early-stage HCC.
BRITISH JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Isaac Kyei-Barffour, Roselind Kyei Baah Kwarkoh, Desmond Omane Acheampong, Augustine Suurinobah Brah, Samuel Addo Akwetey, Benjamin Aboagye
Summary: The study demonstrates that Carica papaya alkaloidal extract exhibits significant anticancer activity in rodent models of HCC, improving weight loss, tumor multiplicity, liver histomorphological changes, and coagulation function. Additionally, the alkaloidal extract effectively reduces serum alpha-fetoprotein levels and prevents the establishment of HCC.
Article
Medical Laboratory Technology
Shan Tian, Yongyi Chen, Yimin Zhang, Xiaohong Xu
Summary: The accuracy of AFP as a diagnostic marker for HCC is insufficient, and the application of PIVKA-II in HCC is still controversial. Combined detection of AFP and PIVKA-II is superior to both tests alone. The level of PIVKA-II is correlated with the severity and prognosis of HCC, while the level of AFP is not.
JOURNAL OF CLINICAL LABORATORY ANALYSIS
(2023)
Review
Biochemistry & Molecular Biology
Endrit Shahini, Giuseppe Pasculli, Antonio Giovanni Solimando, Claudio Tiribelli, Raffaele Cozzolongo, Gianluigi Giannelli
Summary: HCC is the most common primary liver cancer, and its mortality rate is increasing globally. Early diagnosis is critical, and combining novel biomarkers with traditional ones can enhance HCC detection sensitivity. Developing new diagnostic tools and prognostic scores may improve patients' survival.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Multidisciplinary Sciences
Takashi Tanaka, Kazuhide Takata, Takashi Miyayama, Kumiko Shibata, Hiromi Fukuda, Ryo Yamauchi, Atsushi Fukunaga, Keiji Yokoyama, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai
Summary: Percutaneous radiofrequency ablation (RFA) is an effective treatment for small hepatocellular carcinoma (HCC) with a diameter <= 3.0 cm. However, for HCC with a diameter > 3.0 cm, the treatment outcomes are influenced by prognostic factors such as distant tumor recurrence, Child-Pugh class, and pre-ablation des-gamma-carboxy prothrombin (DCP) levels.
SCIENTIFIC REPORTS
(2023)
Article
Oncology
Norikazu Tanabe, Issei Saeki, Yuki Aibe, Takashi Matsuda, Tadasuke Hanazono, Maiko Nishi, Isao Hidaka, Shinya Kuwashiro, Shogo Shiratsuki, Keiji Matsuura, Maho Egusa, Natsuko Nishiyama, Tsuyoshi Fujioka, Daiki Kawamoto, Ryo Sasaki, Tatsuro Nishimura, Takashi Oono, Takuro Hisanaga, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Takahiro Yamasaki, Taro Takami
Summary: The combination therapy of atezolizumab and bevacizumab was introduced as a first-line treatment for unresectable hepatocellular carcinoma in 2020. This study investigated early predictors of treatment response and disease progression based on baseline alpha-fetoprotein (AFP) levels. The results highlighted the usefulness of changes in AFP and baseline levels of des-gamma-carboxy prothrombin in predicting treatment response.
Article
Oncology
Yang-Xun Pan, Xu-Qi Sun, Zi-Li Hu, Wa Xie, Ke-Xin Nie, Ai-Ping Fang, Ying-Yao Zhang, Yi-Zhen Fu, Jin-Bin Chen, Jun-Cheng Wang, Xin Wang, Yao-Jun Zhang, Dan-Dan Hu, Min-Shan Chen
Summary: This study comprehensively analyzed AFP and DCP data for HCC patients in a hepatitis B virus epidemic area, finding a high positivity rate of AFP and DCP, and patients with poor treatment response had worse survival outcomes.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2021)
Article
Gastroenterology & Hepatology
Jihyeon Lee, Young-Suk Lim, Jeong-Hoon Lee, Geum-Youn Gwak, Misol Do, Injoon Yeo, Dongyoon Shin, Dohyun Han, Taesung Park, Youngsoo Kim
Summary: The study focused on improving the DCP measurement assay using a mass spectrometry-based approach, which resulted in a more inclusive quantification of various DCP proteoforms. The MS-based quantitative assay showed reliable surveillance power and was found to be superior to conventional antibody-based quantification in terms of cost-effectiveness and reproducibility.
HEPATOLOGY COMMUNICATIONS
(2021)
Review
Gastroenterology & Hepatology
Hira Hanif, Mukarram Jamat Ali, Ammu T. Susheela, Iman Waheed Khan, Maria Alejandra Luna-Cuadros, Muzammil Muhammad Khan, Daryl Tan-Yeung Lau
Summary: Alpha-fetoprotein (AFP) is a tumor marker for hepatocellular carcinoma (HCC), but its utility is limited. However, combining AFP with other novel biomarkers can improve its accuracy. Additionally, increased AFP levels may be associated with liver diseases and other non-hepatic disorders.
WORLD JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Virology
Yashasavi Sachar, Mayur Brahmania, Renumathy Dhanasekaran, Stephen E. Congly
Summary: Chronic hepatitis B (CHB) infection is a significant risk factor for developing hepatocellular carcinoma (HCC), and screening high-risk patients with CHB is recommended to improve outcomes. However, there is inconsistency in screening recommendations, and identifying high-risk patients would optimize resource utilization.
Article
Oncology
Baocuo Gong, Xuewen Wang, Wanting Guo, Hongyi Yang, Yanhong Shi, Yaying Chen, Simiao Gao, Jialin Chen, Lifang Liu, Linbin Lu, Xiong Chen, Fujian HCC-biomarker Study Group Fujian HCC-Biomarker Study Grp
Summary: In this study, the prognostic value of the ALFP score was confirmed in predicting the survival of HCC patients undergoing TACE. The score incorporates easily obtainable baseline parameters and provides a simple and practical tool for risk stratification and treatment decision-making in HCC patients.
JOURNAL OF HEPATOCELLULAR CARCINOMA
(2023)
Article
Multidisciplinary Sciences
Francisco Villalba-Lopez, Luis Francisco Saenz-Mateos, Maria Isabel Sanchez-Lorencio, Virginia De La Orden-Garcia, Felipe Alconchel-Gago, Pedro Antonio Cascales-Campos, Carmen Garcia-Bernardo, Jose Antonio Noguera-Velasco, Alberto Baroja-Mazo, Pablo Ramirez-Romero
Summary: The study aimed to evaluate the clinical contribution of protein induced by vitamin K absence or antagonist-II (PIVKA-II) for hepatocellular carcinoma (HCC) monitoring after liver transplantation (LT) and compare it with alpha-foetoprotein (AFP). The results showed significant correlations between PIVKA-II expression levels and clinicopathological features such as tumor size and number of pre-transplant transarterial chemoembolizations (TACEs). PIVKA-II levels decreased significantly after LT and increased in patients with tumor recurrence, suggesting its potential as a novel biomarker for predicting disease severity and early recurrence.
SCIENTIFIC REPORTS
(2023)
Article
Multidisciplinary Sciences
Tianying Ren, Xu Hou, Xin Zhang, Dongliang Chen, Juan Li, Yingnan Zhu, Zhiheng Liu, Dawei Yang
Summary: In this study, we developed the AALP model to differentiate between HCC and CLD patients based on serum biomarkers. The AALP model showed good sensitivity and specificity for HCC detection, and also performed well in the subgroup of CLD patients. Furthermore, we demonstrated the consistency between AFP-L3 and PIVKA II levels and imaging results.